O	0	1	A
O	2	12	randomized
O	13	18	phase
O	19	21	II
O	22	27	study
O	28	38	evaluating
B-intervention	39	49	pyridoxine
O	50	53	for
O	54	57	the
O	58	68	prevention
O	69	71	of
B-condition	72	76	hand
I-condition	76	77	-
I-condition	77	81	foot
I-condition	82	90	syndrome
O	91	101	associated
O	102	106	with
O	107	119	capecitabine
O	120	127	therapy
O	128	131	for
O	132	140	advanced
O	141	143	or
O	144	154	metastatic
O	155	161	breast
O	162	168	cancer
O	168	169	.

O	170	180	Pyridoxine
O	180	181	,
O	182	184	an
O	185	194	activated
O	195	199	form
O	200	202	of
O	203	210	vitamin
O	211	213	B6
O	214	218	used
O	219	221	to
O	222	227	treat
O	228	236	allergic
O	237	247	dermatitis
O	247	248	,
O	249	252	may
O	253	260	prevent
O	261	273	capecitabine
O	273	274	-
O	274	284	associated
O	285	289	hand
O	289	290	-
O	290	294	foot
O	295	303	syndrome
O	304	305	(
O	305	308	HFS
O	308	309	)
O	309	310	,
O	311	319	although
O	320	328	evidence
O	329	331	of
O	332	335	the
O	336	343	benefit
O	344	346	of
O	347	359	prophylactic
O	360	370	pyridoxine
O	371	373	is
O	374	381	lacking
O	381	382	.

O	383	386	The
O	387	390	aim
O	391	393	of
O	394	398	this
O	399	403	open
O	403	404	-
O	404	409	label
O	409	410	,
O	411	422	multicenter
O	422	423	,
O	424	434	randomized
O	435	440	phase
O	441	443	II
O	444	449	study
O	450	453	was
O	454	456	to
O	457	466	determine
O	467	474	whether
O	475	487	prophylactic
O	488	498	pyridoxine
O	499	504	could
O	505	510	delay
O	511	514	the
O	515	520	onset
O	521	523	of
O	524	536	capecitabine
O	536	537	-
O	537	544	induced
O	545	548	HFS
O	549	551	in
B-eligibility	552	560	patients
I-eligibility	561	565	with
I-eligibility	566	574	advanced
I-eligibility	575	577	or
I-eligibility	578	588	metastatic
I-eligibility	589	595	breast
I-eligibility	596	602	cancer
O	602	603	.

O	604	612	Patients
O	613	621	received
O	622	628	either
O	629	640	concomitant
O	641	651	pyridoxine
O	652	653	(
O	653	655	60
O	656	658	mg
O	659	662	per
O	663	666	day
O	666	667	;
O	668	678	pyridoxine
O	679	684	group
O	684	685	)
O	685	686	,
O	687	689	or
B-control	690	692	no
I-control	693	703	pyridoxine
O	704	707	but
O	708	717	treatment
O	718	722	with
O	723	735	capecitabine
O	735	736	-
O	736	746	containing
O	747	755	regimens
O	756	757	(
O	757	759	no
O	760	770	pyridoxine
O	771	776	group
O	776	777	)
O	777	778	.

O	779	784	Study
O	785	794	treatment
O	795	798	was
O	799	811	administered
O	812	817	until
O	818	821	the
O	822	833	development
O	834	836	of
O	837	842	grade
O	843	844	2
O	845	847	or
O	848	853	worse
O	854	857	HFS
O	858	860	or
O	861	868	disease
O	869	880	progression
O	880	881	.

O	882	885	The
O	886	893	primary
O	894	902	endpoint
O	903	906	was
O	907	910	the
B-outcome-Measure	911	915	time
I-outcome-Measure	916	918	to
I-outcome-Measure	919	924	onset
I-outcome-Measure	925	927	of
I-outcome-Measure	928	933	grade
I-outcome-Measure	934	935	2
I-outcome-Measure	936	938	or
I-outcome-Measure	939	944	worse
I-outcome-Measure	945	948	HFS
O	949	953	from
O	954	957	the
O	958	963	start
O	964	966	of
O	967	975	protocol
O	976	985	treatment
O	985	986	.

O	987	988	A
O	989	994	total
O	995	997	of
B-total-participants	998	1001	135
O	1002	1010	patients
O	1011	1015	were
O	1016	1026	randomized
O	1027	1029	to
O	1030	1033	the
O	1034	1044	pyridoxine
O	1045	1046	(
O	1046	1047	n
O	1048	1049	=
B-intervention-participants	1050	1052	67
O	1052	1053	)
O	1054	1056	or
O	1057	1059	no
O	1060	1070	pyridoxine
O	1071	1072	(
O	1072	1073	n
O	1074	1075	=
B-control-participants	1076	1078	68
O	1078	1079	)
O	1080	1086	groups
O	1086	1087	.

B-outcome	1088	1093	Grade
I-outcome	1094	1095	2
I-outcome	1096	1098	or
I-outcome	1099	1104	worse
I-outcome	1105	1108	HFS
O	1109	1118	developed
O	1119	1121	in
B-iv-bin-abs	1122	1124	19
O	1125	1127	of
B-intervention-participants	1128	1130	66
O	1131	1139	patients
O	1140	1141	(
B-iv-bin-percent	1141	1143	28
I-iv-bin-percent	1143	1144	.
I-iv-bin-percent	1144	1145	8
I-iv-bin-percent	1145	1146	%
O	1146	1147	)
O	1148	1154	versus
B-cv-bin-abs	1155	1157	21
O	1158	1160	of
B-control-participants	1161	1163	67
O	1164	1172	patients
O	1173	1174	(
B-cv-bin-percent	1174	1176	31
I-cv-bin-percent	1176	1177	.
I-cv-bin-percent	1177	1178	3
I-cv-bin-percent	1178	1179	%
O	1179	1180	)
O	1181	1183	in
O	1184	1187	the
O	1188	1198	pyridoxine
O	1199	1202	and
O	1203	1205	no
O	1206	1216	pyridoxine
O	1217	1223	groups
O	1223	1224	,
O	1225	1237	respectively
O	1237	1238	.

O	1239	1242	The
B-outcome	1243	1249	median
I-outcome	1250	1254	time
I-outcome	1255	1257	to
I-outcome	1258	1263	onset
I-outcome	1264	1266	of
I-outcome	1267	1272	grade
I-outcome	1273	1274	2
I-outcome	1275	1277	or
I-outcome	1278	1283	worse
I-outcome	1284	1287	HFS
O	1288	1291	was
B-iv-cont-median	1292	1294	13
I-iv-cont-median	1294	1295	.
I-iv-cont-median	1295	1296	6
O	1297	1300	and
B-cv-cont-median	1301	1303	10
I-cv-cont-median	1303	1304	.
I-cv-cont-median	1304	1305	6
I-cv-cont-median	1306	1312	months
O	1313	1315	in
O	1316	1319	the
O	1320	1330	pyridoxine
O	1331	1334	and
O	1335	1337	no
O	1338	1348	pyridoxine
O	1349	1355	groups
O	1355	1356	,
O	1357	1369	respectively
O	1370	1371	[
O	1371	1377	hazard
O	1378	1383	ratio
O	1384	1385	=
O	1386	1387	0
O	1387	1388	.
O	1388	1390	75
O	1391	1392	(
O	1392	1394	80
O	1394	1395	%
O	1396	1406	confidence
O	1407	1415	interval
O	1416	1417	0
O	1417	1418	.
O	1418	1420	50
O	1420	1421	-
O	1421	1422	1
O	1422	1423	.
O	1423	1425	13
O	1425	1426	)
O	1426	1427	,
O	1428	1431	one
O	1431	1432	-
O	1432	1437	sided
O	1438	1439	P
O	1440	1441	=
O	1442	1443	0
O	1443	1444	.
O	1444	1446	18
O	1446	1447	]
O	1447	1448	.

O	1449	1461	Prophylactic
O	1462	1472	pyridoxine
O	1473	1476	was
O	1477	1480	not
O	1481	1486	shown
O	1487	1489	to
O	1490	1494	have
O	1495	1497	an
O	1498	1504	effect
O	1505	1507	on
O	1508	1511	the
O	1512	1517	onset
O	1518	1520	of
O	1521	1533	capecitabine
O	1533	1534	-
O	1534	1544	associated
O	1545	1548	HFS
O	1549	1551	in
O	1552	1556	this
O	1557	1562	study
O	1562	1563	.
